Dasatinib Reduces Cetuximab Resistance in KRAS and BRAF Mutated Colorectal Carcinoma Cells Through Inhibiting Matrix-Dependent Cell Migration

Dasatinib Reduces Cetuximab Resistance in KRAS and BRAF Mutated Colorectal Carcinoma Cells Through Inhibiting Matrix-Dependent Cell Migration

碩士 === 東海大學 === 生命科學系 === 107

Bibliographic Details
Main Authors:	CHIU, HSIANG-LING, 邱相齡
Other Authors:	CHAO, WEI-TING
Format:	Others
Language:	en_US
Published:	2019
Online Access:	http://ndltd.ncl.edu.tw/handle/64g897

Similar Items

Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab
by: Justine Bellier, et al.
Published: (2020-02-01)

Molecular understanding of KRAS- and BRAF-mutated colorectal cancers
by: Lundberg, Ida
Published: (2017)

The Possible Therapeutic Strategy for Colorectal Cancer with KRAS/BRAF Mutations
by: Jing-Jung Chen, et al.
Published: (2012)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
by: Giandomenico Roviello, et al.
Published: (2020-09-01)

KRAS mutations as a predictor of response to Cetuximab in metastatic colorectal cancer patients
by: Li-Chen Yen, et al.
Published: (2010)

ANALYSIS OF MUTATIONS IN KRAS AND BRAF GENES IN COLORECTAL CANCER IN RUSSIAN PATIENTS
by: E. E. Pisareva, et al.
Published: (2016-07-01)

Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis
by: Snehangshu Kundu, et al.
Published: (2021-07-01)

The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
by: Daeyoun David Won, et al.
Published: (2017-06-01)

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients.
by: Zacharenia Saridaki, et al.
Published: (2011-01-01)

Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
by: Omer Bayrak, et al.
Published: (2014-08-01)

Colorectal Cancer Prognosis is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study
by: Joon-Hyop Lee, et al.
Published: (2019-01-01)

KRAS, p53 and BRAF Gene Mutations and Aneuploidy in Sporadic Colorectal Cancer Progression
by: Daniele Calistri, et al.
Published: (2006-01-01)

Beyond <it>KRAS</it> mutation status: influence of <it>KRAS</it> copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
by: Mekenkamp Leonie JM, et al.
Published: (2012-07-01)

Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study
by: Chunlong Huang, et al.
Published: (2021-01-01)

Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression
by: Manzari, Mandana T., et al.
Published: (2014)

KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis
by: Abolfazl Yari, et al.
Published: (2020-06-01)

Mitochondrial Respiration in <i>KRAS</i> and <i>BRAF</i> Mutated Colorectal Tumors and Polyps
by: Egle Rebane-Klemm, et al.
Published: (2020-03-01)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
by: Qiwei Yang, et al.
Published: (2018-10-01)

KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?
by: Nicolas Piton, et al.
Published: (2015-01-01)

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
by: Sally Temraz, et al.
Published: (2015-09-01)

Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer
by: Hutton, Josiah Ewing
Published: (2016)

Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations
by: Raphaela Fritsche-Guenther, et al.
Published: (2018-06-01)

KRAS, NRAS, and BRAF Mutation Pattern in Metastatic Colorectal Cancer: A Study from Northwest Iran
by: Roya Dolatkhah, et al.
Published: (2019-08-01)

Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A case report supporting the concept of tumoral heterogeneity
by: Pegah Larki, et al.
Published: (2017-05-01)

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
by: S. Gattenlöhner, et al.
Published: (2009-01-01)

KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer.
by: Chen Mao, et al.
Published: (2012-01-01)

Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component
by: Xiaodong Li, et al.
Published: (2020-05-01)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
by: Sergiu Pasca, et al.
Published: (2019-10-01)

KRAS and BRAF Mutation in Borderline Epithelial Type Ovarian Tumor
by: Dodi Suardi
Published: (2013-04-01)

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
by: Erik J. vanHelden, et al.
Published: (2019-11-01)

<it>BRAF</it>, <it>KRAS </it>and <it>PIK3CA </it>mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?
by: Schmitt Fernando, et al.
Published: (2008-09-01)

Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study
by: Hooria Momenzadeh, et al.
Published: (2018-01-01)

Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer.
by: Claire Franczak, et al.
Published: (2020-01-01)

One-carbon metabolism biomarkers and genetic variants in relation to colorectal cancer risk by KRAS and BRAF mutation status.
by: Robin Myte, et al.
Published: (2018-01-01)

Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer
by: Luca Reggiani Bonetti, et al.
Published: (2018-01-01)

BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
by: Suhail Al-Salam, et al.
Published: (2020-01-01)

KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia.
by: Miriam Juárez, et al.
Published: (2017-01-01)

BRAF mutation in colorectal carcinomas with signet ring cell component
by: Serap Yalcin, et al.
Published: (2017-06-01)

Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma
by: Cheng L, et al.
Published: (2015-11-01)

INFLUENCE OF SOMATIC MUTATIONS OF KRAS, NRAS, BRAF AND MICROSATELLITE INSTABILITY STATUS ON SURVIVAL OF COLORECTAL CANCER PATIENTS WITH PERITONAL CARCINO
by: V. P. Shubin, et al.
Published: (2020-10-01)